Cellectis is a clinical stage biotechnological company. Co. is developing a series of product candidates for hematologic cancers. Co.'s primary immuno-oncology product candidates, which it refers to as Universal Chimeric Antigen Receptor T-cells, are allogeneic CAR T-cells engineered to be used as an off-the-shelf treatment. UCART is a therapeutic product line that it is developing with its gene-editing platform to address unmet medical needs in oncology. Co. is focusing its initial internal pipeline in the hematologic cancer space, targeting diseases such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma and other types of cancers. The CLLS YTD return is shown above.
The YTD Return on the CLLS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CLLS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CLLS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|